2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2176

The Association of Gout with Incident Giant Cell Arteritis in Older Adults
Abstract Number: 2177

Workforce Requirements in Rheumatology: A Systematic Literature Reviewinforming the Development of a Workforce Prediction Risk of Bias Tool and the EULAR Points to Consider
Abstract Number: 2178

Provider Perceptions of Telerheumatology within the Veterans Health Administration: A National Survey Study
Abstract Number: 2179

Poor Rates of Screening for Retinal Toxicity in Patients on Antimalarial Medications: A Population-Based Study
Abstract Number: 2180

Differences in Longitudinal Disease Activity Measures between Research Cohort and Non-Cohort Participants with Rheumatoid Arthritis Using Electronic Health Record Data
Abstract Number: 2181

Development and Feasibility of a Web-Based Data Capture System to Collect Uniform Comprehensive Post-Total Knee Replacement Physical Therapy Intervention Data for Both Clinical and Research Purposes
Abstract Number: 2182

Defining Alendronate Drug Holidays and Re-Initiation in US Medicare Data
Abstract Number: 2183

Access to Prescription Drugs in Canada: Results from an Online Survey
Abstract Number: 2184

An Economic Evaluation on the Impact of Earlier Systemic Lupus Erythematosus (SLE) Diagnosis Using Complement C4d Activation Products in a Multivariate Assay Panel (MAP)
Abstract Number: 2185

Direct Medical Costs for Medicare Patients with Rheumatoid Arthritis
Abstract Number: 2186

Process Evaluation of a Culturally-Sensitive, Community Based Self-Management Program for First Nations People with Arthritis and Their Families
Abstract Number: 2187

Specialist Link Telephone Advice Cost Effectively Enhances Rheumatology Patient Care in Alberta, Canada
Abstract Number: 2188

Regional Analysis of Impact of Participation in a Patient Support Program on Clinical Outcomes Among Patients with Rheumatoid Arthritis Receiving Adalimumab (Humira)
Abstract Number: 2189

Use of Smartphones in Collecting Patient Reported Outcomes (PROs): Feasibility of a Study Nested in a US National Cohort
Abstract Number: 2190

Means of Collaboration between Ophthalmologists, Rheumatologists and Internists in the Management of Non-Infectious Uveitis: A Nationwide Study

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].